PDF(Pubmed)
Abstract：
UNASSIGNED: Several medications used to treat attention deficit hyperactivity disorder (ADHD) have been associated with diminished bone mineral density (BMD) in children. The objective of this study was to determine if evidence exists for a similar association among adults.
UNASSIGNED: A retrospective cross-sectional analysis was conducted using data collected by the National Health Nutrition Examination Survey 2013-2018. Data from 7961 individuals aged 18 to 50, 79 of whom were taking medications to treat ADHD. Dual-energy X-ray absorptiometry scans provided measure of body composition. Linear regression models were used to examine associations between ADHD medication use and body composition.
UNASSIGNED: Stimulant ADHD medication usage was found to be associated with decreased BMD in both the skull (-6.6%; 95% CI 5.9-7.2) (P < 0.05) and thoracic spine (-6.0%; 95% CI 5.1-7.0) (P < 0.05). No difference in BMD was seen in any other skeletal region based on stimulant ADHD medication use (P > 0.05). We found no evidence to suggest that duration of use affected the observed decreases in BMD, P > 0.05.
UNASSIGNED: This study using a nationally representative sample assessed whether stimulant medication use in adults with ADHD was associated with decreased BMD. The overall results are inconclusive. Further study is needed to better evaluate if ADHD and/or stimulant medication use is independently associated with bone health.
UNASSIGNED: A retrospective cross-sectional analysis was conducted using data collected by the National Health Nutrition Examination Survey 2013-2018. Data from 7961 individuals aged 18 to 50, 79 of whom were taking medications to treat ADHD. Dual-energy X-ray absorptiometry scans provided measure of body composition. Linear regression models were used to examine associations between ADHD medication use and body composition.
UNASSIGNED: Stimulant ADHD medication usage was found to be associated with decreased BMD in both the skull (-6.6%; 95% CI 5.9-7.2) (P < 0.05) and thoracic spine (-6.0%; 95% CI 5.1-7.0) (P < 0.05). No difference in BMD was seen in any other skeletal region based on stimulant ADHD medication use (P > 0.05). We found no evidence to suggest that duration of use affected the observed decreases in BMD, P > 0.05.
UNASSIGNED: This study using a nationally representative sample assessed whether stimulant medication use in adults with ADHD was associated with decreased BMD. The overall results are inconclusive. Further study is needed to better evaluate if ADHD and/or stimulant medication use is independently associated with bone health.
摘要：
未经证实：几种用于治疗注意力缺陷多动障碍（ADHD）的药物与儿童骨密度（BMD）降低有关。这项研究的目的是确定成年人之间是否存在类似关联的证据。
UNASSIGNED：使用2013-2018年国家健康营养检查调查收集的数据进行了回顾性横断面分析。数据来自7961名年龄在18至50岁之间的人，其中79人正在服用药物治疗ADHD。双能X射线吸收测量扫描提供了身体成分的测量。使用线性回归模型来检查ADHD药物使用与身体组成之间的关联。
未经证实：发现使用兴奋剂ADHD与颅骨（-6.6％；95％CI5.9-7.2）（P<0.05）和胸椎（-6.0％；95％CI5.1-7.0）（P<0.05）的骨密度降低有关。根据使用刺激性ADHD药物，在任何其他骨骼区域的BMD均无差异（P>0.05）。我们发现没有证据表明使用时间会影响观察到的BMD下降，P>0.05。
UNASSIGNED：这项研究使用具有全国代表性的样本评估了成人多动症患者使用兴奋剂是否与骨密度降低相关。总体结果尚无定论。需要进一步研究以更好地评估ADHD和/或兴奋剂药物使用是否与骨骼健康独立相关。
UNASSIGNED：使用2013-2018年国家健康营养检查调查收集的数据进行了回顾性横断面分析。数据来自7961名年龄在18至50岁之间的人，其中79人正在服用药物治疗ADHD。双能X射线吸收测量扫描提供了身体成分的测量。使用线性回归模型来检查ADHD药物使用与身体组成之间的关联。
未经证实：发现使用兴奋剂ADHD与颅骨（-6.6％；95％CI5.9-7.2）（P<0.05）和胸椎（-6.0％；95％CI5.1-7.0）（P<0.05）的骨密度降低有关。根据使用刺激性ADHD药物，在任何其他骨骼区域的BMD均无差异（P>0.05）。我们发现没有证据表明使用时间会影响观察到的BMD下降，P>0.05。
UNASSIGNED：这项研究使用具有全国代表性的样本评估了成人多动症患者使用兴奋剂是否与骨密度降低相关。总体结果尚无定论。需要进一步研究以更好地评估ADHD和/或兴奋剂药物使用是否与骨骼健康独立相关。
